Pharmacokinetic studies in pregnant women

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 184-187

  Anger, G J ^a   Piquette Miller, M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ATENOLOL; CAFFEINE; CARBAMAZEPINE; CEFATRIZINE; CEFAZOLIN; CEFRADINE; CEFUROXIME; DEXTROMETHORPHAN; DIGOXIN; FLUOXETINE; LAMOTRIGINE; LITHIUM; MORPHINE; NELFINAVIR; NORTRIPTYLINE; OXAZEPAM; PARACETAMOL; PHENYTOIN;

ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL ETHICS; PATIENT CARE; PREGNANT WOMAN; PRIORITY JOURNAL; SEIZURE; SPONTANEOUS ABORTION; SYPHILIS;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG THERAPY; EMBRYO, MAMMALIAN; ETHICS, CLINICAL; FEMALE; GESTATIONAL AGE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PATIENT SELECTION; PHARMACOKINETICS; PREGNANCY; PREGNANCY COMPLICATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; PROGRAM DEVELOPMENT; WOMEN'S HEALTH;

EID: 37549014161     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100377     Document Type: Article

References (30)

1. Mitchell, A.A., Hernandez-Diaz, S., Louik, C. & Werler, M.M. Medication use in pregnancy: 1976-2000. Pharmacoepidemiol. Drug Saf. 10, S146 (2001).
2. McBride, W. Thalidomide and congenital abnormalities. Lancet 278, 1358 (1961).
3. Czerniak, R. Gender-based differences in pharmacokinetics in laboratory animals. Int. J. Toxicol. 20, 161-163 (2001).
4. Curry, B. Animal models used in identifying gender-related differences. Int. J. Toxicol. 20, 153-160 (2001).
5. Dawes, M. & Chowienczyk, P.J. Pharmacokinetics in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 15, 819-826 (2001).
6. Dawood, M.Y. Circulating maternal serum progesterone in high-risk pregnancies. Am. J. Obstet. Gynecol. 125, 832-840 (1976).
7. Reynolds, F. Pharmacokinetics. In Clinical Physiology in Obstetrics 3rd edn. (eds. Chamberlain, G. & Pipkin, F.B.) 239-260 (Blackwell Sciences, London, 1998).
8. Vickers, M. & Brackley, K. Drugs in pregnancy. Curr. Obstet. Gynaecol. 12, 131-137 (2002).
9. Mattison, D. & Zajicek, A. Gaps in knowledge in treating pregnant women. Gend. Med. 3, 169-182 (2006).
10. Schwartz, J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42, 107-121 (2003).
11. de Maat, M.M. et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther. Drug Monit. 25, 367-373 (2003).
12. Little, B.B. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet. Gynecol. 93, 858-868 (1999).
13. de Haan, G.J. et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 63, 571-573 (2004).
14. Pennell, P.B. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 61, S35-S42 (2003).
15. Nakai, A., Sekiya, I., Oya, A., Koshino, T. & Araki, T. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch. Gynecol. Obstet. 266, 25-29 (2002).
16. Tsutsumi, K. et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin. Pharmacol. Ther. 70, 121-125 (2001).
17. Conrad, K.P. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J. Soc. Gynecol. Investig. 11, 438-448 (2004).
18. Frederiksen, M.C. The drug development process and the pregnant woman. J. Midwifery Womens Health 47, 422-425 (2002).
19. Faden, R. Ethics of studying pregnant women 〈http://www.fda.gov/ cder/present/clinpharm2000/1205preg.txt〉 (2000).
20. FDA. General considerations for the clinical evaluation of drugs 〈http://www.fda.gov/CDER/GUIDANCE/old034fn.pdf〉 (Health and Human Services, 1977).
21. Sawle, G. Epilepsy and anticonvulsant drugs. In Prescribing in Pregnancy 3rd edn. (ed. Rubin, P.) 112-126 (BMJ Books, London, 2000).
22. Yerby, M.S. et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res. 5, 223-228 (1990).
23. FDA study and evaluation of gender differences in the clinical evaluation of drugs 〈http://www.fda.gov/CDER/GUIDANCE/old036fn.pdf〉 (Health and Human Services, 1993).
24. FDA pharmacokinetics in pregnancy - study design, data analysis, and impact on dosing and labeling. 〈http://www.fda.gov/CDER/GUIDANCE/5917dft. pdf〉 (Health and Human Services, 2004).
25. Gedeon, C. & Koren, G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 27, 861-868 (2006).
26. Papantoniou, N. et al. Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution. Fetal Diagn. Ther. 22, 100-106 (2007).
27. Tomson, G., Lunell, N.O., Sundwall, A. & Rane, A. Placental passage of oxazepam and its metabolism in mother and newborn. Clin. Pharmacol. Ther. 25, 74-81 (1979).
28. Gerdin, E., Salmonson, T., Lindberg, B. & Rane, A. Maternal kinetics of morphine during labour. J. Perinat. Med. 18, 479-487 (1990).
29. Villani, P. et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br. J. Clin. Pharmacol. 62, 309-315 (2006).
30. Simpson, K.H., Stakes, A.F. & Miller, M. Pregnancy delays paracetamol absorption and gastric emptying in patients undergoing surgery. Br. J. Anaesth. 60, 24-27 (1988).